Clarity Pharmaceuticals has signed a supply agreement with Nusano Inc. for copper-67, expanding its U.S.-based isotope sourcing as it prepares for a Phase III trial of its prostate cancer therapy.

The Sydney-based company will receive copper-67 produced at Nusano’s West Valley City, Utah facility, which is scheduled to begin operations in late 2025. Copper-67 deliveries are expected to begin by mid-2026.

Clarity's lead candidate, 67Cu-SAR-bisPSMA, is being developed for the treatment of prostate cancer and is currently in a Phase I/IIa trial in the U.S. The therapy has been granted Fast Track Designation by the FDA. The upcoming Phase III trial would mark a key step toward regulatory approval and commercialization.
Executive chairperson Dr. Alan Taylor said the agreement supports the company’s plan to secure a scalable and diversified supply chain for copper-67, an isotope used in targeted radiopharmaceutical therapies. “We are excited to continue growing our supply network for copper-67 in preparation for a registrational Phase III clinical trial,” Taylor said.

Clarity’s U.S. supply chain also includes NorthStar Medical Radioisotopes and Idaho State University’s Idaho Accelerator Center.

Nusano’s accelerator-based production methods are designed for high-volume isotope output and do not rely on nuclear reactors. The company also plans to begin producing its own enriched copper-67 starting materials, which could help mitigate supply chain risk and reduce dependency on external sources.

Nusano CEO Chris Lowe said the supply agreement deepens the relationship between the companies. “We are excited to deepen our relationship with Clarity through the signing of this supply agreement for copper-67 to enable their clinical and commercial efforts,” he said.

The initial term of the agreement is three years, with automatic two-year renewals.

67Cu-SAR-bisPSMA remains an unapproved investigational product. Safety and efficacy have not yet been reviewed by the FDA or other regulatory bodies.

U.S. Healthcare Homepage